#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Round cell liposarcoma Oesophageal adenocarcinoma stage II Prophylaxis against transplant rejection Arrhythmia Bladder cancer Neuroblastoma recurrent Neuroendocrine carcinoma metastatic Oropharyngeal squamous cell carcinoma Acquired C1 inhibitor deficiency Malignant glioma Angiosarcoma recurrent Neurofibromatosis Desmoid tumour Microscopic polyangiitis Non-Hodgkin's lymphoma More trials…

    Learn about Rare Diseases

    Ornithine transcarbamoylase deficiency Congenital generalised lipodystrophy Atypical haemolytic uraemic syndrome – Basic Information Thrombotic thrombocytopenic purpura – Life with Disease Glomerulonephritis membranous – Diagnostics Pleural mesothelioma malignant Wolfram syndrome – Diagnostics Familial amyotrophic lateral sclerosis – Trials in Disease Uterine leiomyosarcoma – Diagnostics Cytokine release syndrome – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Montelukast Rifampicin Deferoxamine ASP3082 Isaralgagene Civaparvovec Corline Heparin Conjugate APROTININ Dactylis Glomerata Ale.c04 Dexlansoprazole OMEGA-3-ACID ETHYL ESTERS 90 [99MTC]PSMA I&S Magnesium Hydroxide Nirogacestat Hydrobromide Tioguanine Dantrolene Sodium Sonidegib Fluoroestradiol F-18 Clic-1901 Cart Milrinone More therapies…

    Learn about Your Condition

    Bipolar disorder Ehlers-Danlos syndrome Asymptomatic HIV infection Benign neoplasm of ureter Retinal vein occlusion Respiratory failure Neurofibromatosis Polymyositis Infertility female Neurofibrosarcoma Osteogenesis imperfecta Neutropenia Immune-mediated enterocolitis Ovarian cancer Pulmonary alveolar haemorrhage More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Hospitalier Universitaire Rouen

Centre Hospitalier Universitaire Rouen

1 Rue De Germont, Bp 96031, Rouen, 76031, France

Want to learn more about this study or check if you can participate? Contact us.

  • Evaluating the use of capecitabine, oxaliplatin, fluorouracil, folinic acid, and irinotecan to personalize chemotherapy for patients with stage III colorectal cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Capecitabine
    • Fluorouracil
    • Folinic Acid
    France Sweden

  • A study to assess the safety of Anumigilimab in adults with sickle cell disease

    Recruiting

    2 1
    Investigated Drugs:
    • ANUMIGILIMAB
    Belgium France Italy The Netherlands

  • Comparing Sotorasib and Pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Hydroxocobalamin
    • Sotorasib
    • Betamethasone Sodium Phosphate Ph. Eur
    Austria Belgium Bulgaria Czechia Denmark France +11

  • A study comparing one month versus one year of aspirin and clopidogrel treatment in patients with chronic limb-threatening ischemia after below-the-knee vascular therapy.

    Recruiting

    3 1 1
    Investigated Diseases:
    • Peripheral artery angioplasty
    • Peripheral artery thrombosis
    • Peripheral arterial occlusive disease
    Investigated Drugs:
    • Clopidogrel
    France

  • A safety and efficacy study of SAR445399 in adults with moderate to severe hidradenitis suppurativa

    Recruiting

    2 1
    Investigated Drugs:
    • SAR445399
    Belgium France Germany Hungary Italy Spain +1

  • A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

    Recruiting

    3 1
    Investigated Drugs:
    • Remibrutinib
    Austria Belgium Bulgaria Croatia Czechia Denmark +19

  • A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

    Recruiting

    3 1
    Investigated Diseases:
    • Arteriosclerosis
    Austria Belgium Bulgaria Czechia Estonia France +10

  • A study to evaluate the use of diroximel fumarate to reduce brain swelling in patients with a stroke caused by bleeding in the brain.

    Recruiting

    3 1 1
    Investigated Diseases:
    • Cerebral haemorrhage
    Investigated Drugs:
    • Diroximel Fumarate
    France

  • A study evaluating the efficacy and safety of secukinumab compared to a drug combination in patients with severe Takayasu arteritis.

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Adalimumab
    • Infliximab
    • Secukinumab
    France

  • A study testing prednisone combined with antibiotics compared to antibiotics alone in adults with septic arthritis to improve joint health

    Recruiting

    3 1 1
    Investigated Diseases:
    • Arthritis infective
    Investigated Drugs:
    • Prednisone
    France
Previous Page
1 2 3 4 … 48
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!